medigraphic.com
Boletín Médico del Hospital Infantil de México

2010, Number 6

<< Back Next >>

Bol Med Hosp Infant Mex 2010; 67 (6)

Meningococcal disease: is it a latent disease in Mexico?

Gómez BD, Espinosa MLE, Moreno ES, Chacón CE, Mata-Miranda P, Rodríguez SRS

Language: English
References: 82
Page: 555-566
PDF size: 334.51 Kb.


Text Extraction

Infection by Neisseria meningitidis occurs first as an asymptomatic carrier before the disease with serious manifestations like meningitis, with or without expressions of fulminating purpura. This disease is caused by different serogroups, A, B, C, Y and W-135 being the most prevalent. Over time they have undergone epidemiological changes in different regions of the world. There is scant information in our country concerning both the carrier and the invading forms; however, it has been proven in some Mexican states that the incidence of carrier status and of invading forms is significant. Accordingly, the possibilities of invading and secondary cases derived from the carrier and through contact with invading forms are feasible. Therefore, increasing the epidemiological surveillance and determining the actual burden of meningococcal disease is required. As far as preventive measures are concerned, prophylaxis of contacts with the index case and vaccination to control outbreaks or in high-risk specific cases is recommended. It would be reasonable as well to establish the indications of the vaccines available in our country.


REFERENCES

  1. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 1985;7:504-510.

  2. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998;106:505-525.

  3. Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94:271-276.

  4. Bilukha OO, Rosenstein N, National center of Infectious Diseases, Center for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMRW Recomm Rep 2005;54(RR-7):1-21.

  5. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981;99:540-545.

  6. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996;15:967-978.

  7. Riedo FX, Plikaytis BD, Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995;14:643-657.

  8. Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 1977;9:105-110.

  9. Nassif X. Interaction mechanisms of encapsulated meningococci with eucaryotic cells: what does this tell us about the crossing of the blood-brain barrier by Neisseria meningitidis? Curr Opin Microbiol 1999;2:71-77.

  10. Stephens DS, Farley MM. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 1991;13:22-33.

  11. Greenfield S, Sheehe PR, Feldman HA. Meningococcal carriage in a population of “normal” families. J Infect Dis 1971;123:67-73.

  12. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987;99:591-601.

  13. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999;353:941-942.

  14. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, Slack RC, Madeley RJ, Ait-Tahar K, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000;320:846-849.

  15. Caugant DA, Høiby EA, Magnus P, Scheel O, Hoel T, Bjune G, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994;32:323-330.

  16. Sparling PF. A plethora of host factors that determine the outcome of meningococcal infection. Am J Med 2002;112:72-74.

  17. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-1326.

  18. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000;13:144-166.

  19. Aycock WL, Mueller JH, Carroll FB. Meningococcus carrier rates and meningitis incidence. Bacteriol Rev 1950;14:115-160.

  20. Active Bacterial Core Surveillance (ABCs) (1997-2002). Meningococcal surveillance reports. Available at: www.cdc.gov/ncidod/dbmd/abcs/ (Accessed: 7-15-2004).

  21. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-7):1-10.

  22. Sistema Nacional de Vigilancia Epidemiológica. Anuarios de Morbilidad de la Dirección General de Epidemiología, 2002-2004. Available at: http://www.dgepi.salud.gob.mx/2010/plantilla/anuarios.html

  23. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrob Agents 2003;21:102-106.

  24. Padron F. Meningitis meningocóccica en los niños. Rev Med Hosp Central San Luis Potosi 1949;1:193-218.

  25. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001;19:1327-1346.

  26. Robbins JB, Myerowitz L, Whisnant JK, Argaman M, Schneerson R, Handzel ZT, et al. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun 1972;6:651-656.

  27. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004;53:821-832.

  28. Tabona P, Mellor A, Summerfield JA. Mannose binding protein is involved in first-line host defense: evidence from transgenic mice. Immunology 1995;85:153-159.

  29. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 2004;198:185-202.

  30. Faber J, Schuessler T, Finn A, Murdoch C, Zenz W, Habermehl P, et al. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr Infect Dis J 2007;26:243-246.

  31. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282:417-420.

  32. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2:114-118.

  33. Taunay AE, Feldman RA, Bastos CO, Galvao PA, Morais JS, Castro IO. Assessment of the protection conferred by anti-group C meningococcal polysasacharide vaccine to 6 to 36 month-old children. Rev Inst Adolfo Lutz 1978;38:77-82.

  34. Armand J, Arminjon F, Mynard MC, Lafaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. J Biol Stand 1982;10:335-339.

  35. Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-204.

  36. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165(Suppl 1):S49-S52.

  37. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56:1536-1547.

  38. Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988;16:55-59.

  39. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 1988;260:2686-2689.

  40. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183:160-163.

  41. Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002;70:4946-4954.

  42. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-S67.

  43. Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J 2007;26:371-376.

  44. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-226.

  45. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746.

  46. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Pediatr Child Health 2001;37:S34-S36;S37.

  47. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000;283:2795-2801.

  48. Bose A, Coen P, Tully J, Viner R, Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet 2003;361:675-676.

  49. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-367.

  50. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365-366.

  51. Center for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR 2007;56:1265-1266.

  52. Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24:57-62.

  53. Center for Disease Control and Prevention (CDC). Guillain-Barré syndrome among recipients of Menactra®-meningococcal conjugate vaccine-United States, June-July 2005. MMWR 2005;54:1023-1025.

  54. Center for Disease Control and Prevention (CDC). Inadvertent administration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR 2006;55:1016-1017.

  55. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatrics patients. Pediatrics 2005;116:496-505.

  56. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 2001;286:688-693.

  57. Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003;21:4437-4447.

  58. Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23:429-435.

  59. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-1078.

  60. Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-829.

  61. Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000;38:3323-3328.

  62. Cartwright K, Morris R, Rümke H, Fox A, Borrow R, Begg N, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-2619.

  63. Koch S, Steffen R. Meningococcal disease in travelers: vaccination recommendations. J Travel Med 1994;1:4-7.

  64. Wilder-Smith A, Tai Goh K. W-135 meningococcal disease in a traveler: a case report. J Travel Med 2003;10:59-60.

  65. Riley LK. Bacterial meningitis exposure during an international flight: lessons for communicable pathogens. Aviat Space Environ Med 2006;77:758-760.

  66. O’Connor BA, Chant KG, Binotto E, Maidment CA, Maywood P, McAnulty JM. Meningococcal disease-probable transmission during an international flight. Commun Dis Intell 2005;29:312-314.

  67. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006;24:4692-4700.

  68. Pollard AJ, Shlim DR. Epidemic meningococcal disease and travel. J Travel Med 2002;9:29-33.

  69. Bröker M. Vaccination against meningococcal disease: which vaccine to use? J Travel Med 2002;9:168-169.

  70. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A,C,W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents age 15-25 years. Vaccine 2009;27:161-168.

  71. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299:173-184.

  72. Halperin SA, Diaz-Mitoma F, Anemona A, Ceddia FC. Safety and immunogenicity of Novartis Vaccines MenACWY conjugate vaccine after one or two doses administered to infants and young children. Poster presentation at the 5th World Congress of the World Society for Pediatric Infectious Disease (WSPIP) Annual Meeting, November 2007.

  73. Velsikari T, Ceddia F, Karnoven A, Anemona A, Danzing L, Schmitt HJ. Immune response and immunological memory induced by a novel meningococcal ACWY-CRM conjugate vaccine (Men ACWY) in toddlers. Poster presented at the 23rd Annual Meeting of European Society of Pediatric Infectious Diseases (ESPID), 2005.

  74. Espinosa de los Monteros LE, Aguilar-Ituarte F, Jiménez Rojas LV, Kuri P, Rodríguez Suárez RS, Gómez Barreto D. Prevalence of Neisseria meningitidis carriers in children under five years of age and teenagers in certain populations of Mexico City. Salud Publica Mex 2009;51:114-118.

  75. Chacon Cruz E, Lopez Viera Jl, Lara Muñoz CA, Rivas Landeros RM, Duran Hernandez MC, Voelker ML, et al. High rate of meningococcal disease in Baja California, Mexico: an unknown endemic disease with a rate similar to the USA. Poster presentation at the 13th International Congress on Infectious Diseases, Kuala-Lumpur, Malasia 2008. Abstract #2739.

  76. De Wals P, Hertoghe L, Borlée-Grimée I, De Maeyer-Cleempoel S, Reginster-Haneuse G, Dachy A, et al. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J Infect 1981;3(Suppl 1):53-61.

  77. Jacobson JA, Filice GA, Holloway JT. Meningococcal disease in day-care centers. Pediatrics 1977;59:299-300.

  78. Centers for Disease Control and Prevention (CDC). Guidelines for the management of airlines passengers exposed to meningococcal disease. Available at: http://www.cdc.gov/travel/menin-guidelines.htm

  79. Gilmore A, Stuart J, Andrews N. Risk of secondary meningococcal disease in health-care workers. Lancet 2000;356:1654-1655.

  80. Broome CV. The carrier state: Neisseria meningitidis. J Antimicrob Chemother 1986;18(Suppl A):25-34.

  81. Gaunt PN, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis. J Antimicrob Chemother 1988;21:489-496.

  82. Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 1998;17:816-819.




2020     |     www.medigraphic.com